Roth Capital is stepping to the sidelines on Celsion (CLSN -81%), cutting the shares to Neutral...

|About: Celsion Corporation (CLSN)|By:, SA News Editor

Roth Capital is stepping to the sidelines on Celsion (CLSN -81%), cutting the shares to Neutral on the back of the failed trial results on its experimental liver cancer drug ThermoDox. The technology failed to significantly slow the progression of liver cancer by what appears to be a wide marging, and calls into doubt the drug's near-term viability.